Inspired by our vision of a disease-free world
ZYMEDI is inspired by a long-term vision to create a disease- free world with therapies for even the most challenging diseases. This paradigm shift in healthcare will create more targets, more choices, and more hope.
Transforming the role of ARS to outsmart disease
Our goal is to pave the road from care to cure by transforming the role of aminoacyl-tRNA synthetases (ARSs) to outsmart diseases, especially those that are hard to treat.
ARSs are associated with angiogenesis, inflammation, tumorigenesis, and other important pathophysiologic processes in human diseases. By targeting these pathways and their respective imbalances, we can help restore the body to balance.
Our values embody these 4 tenets
SAFETY OF DRUG
We target the sites of ARSs that would not affect general protein synthesis and would be less likely to cause side effects.
NOVELTY OF TARGET
We are the only company researching ARSs at the systemic level.
CLARITY OF MECHANISM
We clearly demonstrate the working mechanisms of ARSs to the medical community.
SELECTIVITY OF DISEASE
We generate evidence showing the disease-specific behaviors and activities of ARSs.
A leadership team focused on unlocking the full potential of ARS science
Our leadership team is driven to transform the next generation of drug discovery by targeting hard-to-treat disease areas by exploring “emerging biology of ARS.”
The ZYMEDI team has the broad experience with ARS and the depth of knowledge to unlock the full potential of ARS science. Our deep scientific knowledge has shown that targeting ARSs can control disease via multiple pathways, resulting in medicines that are highly efficacious and broadly acting.
Our story
PAH=Pulmonary Arterial Hypertension; NASH=Non-alcoholic Steatohepatitis.
